Anthem Biosciences IPO Debuts Today, Anticipating a Robust 25% Premium
Anthem Biosciences shares are poised to make their debut on the BSE and NSE today, July 21, 2025. This follows a highly successful initial public offering that was oversubscribed by an impressive 63.86 times. The grey market premium (GMP) suggests a promising listing, with shares trading at around ₹713 per share. This reflects a 25.09% premium over the issue price of ₹570 per share.
The ₹3,395 crore IPO, which consisted entirely of an offer-for-sale (OFS) by promoters and shareholders, attracted strong demand from qualified institutional buyers (QIBs) who bid for 182.65 times their reserved category. Anthem Biosciences is an innovation-driven Contract Research, Development and Manufacturing Organization (CRDMO) focused on technology solutions for the pharmaceutical industry. The company’s successful market debut is a testament to investor confidence in India’s burgeoning biotechnology and pharmaceutical sectors.